DelveInsight’s, “Chemotherapy Induced Nausea and Vomiting Pipeline Insight 2025” report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in Chemotherapy Induced Nausea and Vomiting pipeline landscape. It covers the Chemotherapy Induced Nausea and Vomiting pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Chemotherapy Induced Nausea and Vomiting Pipeline. Dive into DelveInsight's comprehensive report today! @ Chemotherapy Induced Nausea and Vomiting Pipeline Outlook
Key Takeaways from the Chemotherapy Induced Nausea and Vomiting Pipeline Report
- In April 2025, Arbeitsgemeinschaft medikamentoese Tumortherapie conducted a phase III trial is to investigate the efficacy and safety of dronabinol (orally administered tetrahydrocannabinol (THC)) as adjuvant therapy to first-line standard chemotherapy in patients with metastatic pancreatic cancer for improvement of chemotherapy- and tumor-related symptoms applicated by individual titration up to the maximum tolerated dose.
- DelveInsight’s Chemotherapy Induced Nausea and Vomiting Pipeline report depicts a robust space with 4+ active players working to develop 6+ pipeline therapies for Chemotherapy Induced Nausea and Vomiting treatment.
- The leading Chemotherapy Induced Nausea and Vomiting Companies such as RedHill Biopharma, Acacia Pharma, Camurus AB, Fujian Shengdi Pharmaceutical Co., Ltd and others.
- Promising Chemotherapy Induced Nausea and Vomiting Pipeline Therapies such as GW679769, Dexamethasone, Ondansetron Hydrochloride, Akynzeo, Fosaprepitant Dimeglumine, Intranasal granisetron, Rolapitant, Granisetron, and others.
Stay ahead with the most recent pipeline outlook for Chemotherapy Induced Nausea and Vomiting. Get insights into clinical trials, emerging therapies, and leading companies with Chemotherapy Induced Nausea and Vomiting @ Chemotherapy Induced Nausea and Vomiting Treatment Drugs
Chemotherapy Induced Nausea and Vomiting Emerging Drugs Profile
- RHB-102: RedHill Biopharma
RHB-102 is a patent-protected, proprietary, once-daily, bimodal extended-release, oral tablet formulation of the antiemetic drug ondansetron, a 5-HT3 antagonist, targeting potential indications including oncology support, acute gastroenteritis and gastritis, and IBS-D at two dose strengths, 12mg and 24mg. RedHill Biopharma entered into an exclusive worldwide development and commercialization licensing agreement, excluding North America, with Hyloris Pharmaceuticals for RHB-102 for gastroenteritis & gastritis, IBS-D and oncology support. Currently, the drug is in Phase III stage of its development for the treatment of Chemotherapy Induced Nausea and Vomiting.
- APD403: Acacia Pharma
APD403 is based on the selective dopamine antagonist amisulpride, the same active ingredient as in Barhemsys®. It is being developed as an intravenous injection for cancer patients to be administered immediately before they receive chemotherapy to prevent acute CINV, and as an oral tablet to prevent delayed CINV. APD403 has successfully completed one proof-of-concept and one Phase II dose-ranging study demonstrating it is well tolerated and effective at preventing acute and delayed CINV. Currently, the drug is in Phase II stage of its development for the treatment of Chemotherapy Induced Nausea and Vomiting.
The Chemotherapy Induced Nausea and Vomiting Pipeline Report Provides Insights into-
- The report provides detailed insights about companies that are developing therapies for the treatment of Chemotherapy Induced Nausea and Vomiting with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chemotherapy Induced Nausea and Vomiting Treatment.
- Chemotherapy Induced Nausea and Vomiting Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Chemotherapy Induced Nausea and Vomiting Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chemotherapy Induced Nausea and Vomiting market
Explore groundbreaking therapies and clinical trials in the Chemotherapy Induced Nausea and Vomiting Pipeline. Access DelveInsight's detailed report now! @ New Chemotherapy Induced Nausea and Vomiting Drugs
Chemotherapy Induced Nausea and Vomiting Companies
RedHill Biopharma, Acacia Pharma, Camurus AB, Fujian Shengdi Pharmaceutical Co., Ltd and others.
Chemotherapy Induced Nausea and Vomiting pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Chemotherapy Induced Nausea and Vomiting Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Unveil the future of Chemotherapy Induced Nausea and Vomiting Treatment. Learn about new drugs, Chemotherapy Induced Nausea and Vomiting Pipeline developments, and key companies with DelveInsight's expert analysis @ Chemotherapy Induced Nausea and Vomiting Market Drivers and Barriers
Scope of the Chemotherapy Induced Nausea and Vomiting Pipeline Report
- Coverage- Global
- Chemotherapy Induced Nausea and Vomiting Companies- RedHill Biopharma, Acacia Pharma, Camurus AB, Fujian Shengdi Pharmaceutical Co., Ltd and others.
- Chemotherapy Induced Nausea and Vomiting Pipeline Therapies- GW679769, Dexamethasone, Ondansetron Hydrochloride, Akynzeo, Fosaprepitant Dimeglumine, Intranasal granisetron, Rolapitant, Granisetron, and others.
- Chemotherapy Induced Nausea and Vomiting Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Chemotherapy Induced Nausea and Vomiting Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Chemotherapy Induced Nausea and Vomiting Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Chemotherapy Induced Nausea and Vomiting Companies, Key Products and Unmet Needs
Table of Contents
- Introduction
- Executive Summary
- Chemotherapy Induced Nausea and Vomiting: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Chemotherapy Induced Nausea and Vomiting– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- RHB-102: RedHill Biopharma
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- APD403: Acacia Pharma
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Chemotherapy Induced Nausea and Vomiting Key Companies
- Chemotherapy Induced Nausea and Vomiting Key Products
- Chemotherapy Induced Nausea and Vomiting- Unmet Needs
- Chemotherapy Induced Nausea and Vomiting- Market Drivers and Barriers
- Chemotherapy Induced Nausea and Vomiting- Future Perspectives and Conclusion
- Chemotherapy Induced Nausea and Vomiting Analyst Views
- Chemotherapy Induced Nausea and Vomiting Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chemotherapy-induced-nausea-and-vomiting-pipeline-insight
